BrainsWay (BWAY) vs InfuSystems (INFU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
InfuSystems (INFU) has outperformed BrainsWay (BWAY) over the past year, gaining 51.7% versus a gain of 13.9%. Over five years, BWAY leads with a +130.7% price change compared with -15.9% for INFU. BrainsWay is the larger company by market cap ($341.3 million vs $287.5 million), about 1.2 times the size.
On valuation, BrainsWay trades at a lower forward P/E (17.0x vs 25.6x for InfuSystems). BrainsWay converts more of its revenue into profit, with a net margin of 7.1% versus 4.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BWAY | INFU |
|---|---|---|
| Share price | $8.48 | $14.35 |
| Market cap | $341.35M | $287.48M |
| 1-day change | -2.86% | +2.06% |
| YTD return | -10.83% | +59.98% |
| 1-year return | +13.90% | +51.69% |
| 5-year return | +130.75% | -15.93% |
| P/E ratio (TTM) | 35.33 | 32.61 |
| Forward P/E | 16.96 | 25.63 |
| EPS (TTM) | $0.24 | $0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.02M | $143.44M |
| Revenue growth (YoY) | +29.04% | +6.36% |
| Net income (latest FY) | $2.92M | $6.63M |
| Gross margin | 74.56% | 55.98% |
| Operating margin | 3.39% | 8.31% |
| Net margin | 7.12% | 4.62% |
| 52-week high | $17.40 | $15.47 |
| 52-week low | $7.30 | $7.29 |
| Distance from 52-week high | -51.26% | -7.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +127.24% | +28.92% |
| Average volume | 110.35K | 136.60K |
| Shares outstanding | 40.25M | 20.03M |
| Employees | 129 | 461 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INFU has outperformed BWAY by 37.8 percentage points over the past year.
- BrainsWay grew revenue faster in its latest fiscal year (+29.04% vs +6.36%).
About BrainsWay
BWAY stock →BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 129 employees
About InfuSystems
INFU stock →InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.
Health Care · Medical/Dental Instruments · 461 employees
BWAY vs INFU FAQ
Which is bigger, BrainsWay or InfuSystems?
BrainsWay (BWAY) is larger, with a market capitalization of $341.35M compared with $287.48M for InfuSystems (INFU).
Which stock has performed better over the past year, BWAY or INFU?
INFU returned +51.69% over the past 12 months, compared with +13.90% for BWAY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BWAY or INFU?
INFU has the lower trailing P/E at 32.6, versus 35.3 for BWAY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BrainsWay and InfuSystems in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.